About this trial
Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.
Eligibility criteria
Qualifiers
Men and women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)>15/hour with CAHI>5/hour, will be included in the experiments
Disqualifiers
less than 18 years old
pregnant or breastfeeding female
have severe respiratory disease that require to be on oxygen
recent health event that may affect the ability to participate in the study,
Trial design
Treatments tested in this trial
- Acetazolamide + supplemental oxygen + PAP therapy
- Zolpidem + PAP therapy
- Buspirone + PAP therapy